Forbion Growth Opportunities Fund III Cooperatief U.A. discloses 12.9% stake in Braveheart Bio
Braveheart Bio
- 12.9%[1]
Forbion Growth Opportunities Fund III Cooperatief U.A. reported a 12.9% stake in Braveheart Bio (BRVE) in a Schedule 13G filed with the SEC on Nov 16, 2026. The filing covers 11,640,546 shares.[1]
| Reporting person | Security | Shares | Ownership | Filed |
|---|---|---|---|---|
| Forbion Growth Opportunities Fund III Cooperatief U.A. | Braveheart Bio, Inc | 11,640,546 | 12.9% | 2026-11-16 |
What is a Schedule 13G?
A Schedule 13G is a passive-holder filing. Holders above five percent of a class must file one. It reports ownership, not a trade price.[1]
What does this filing not show?
The form shows ownership on its cover page. It does not show what the holder paid or what it plans to do next.[1]
BRVE 13F fund activity
In 13F filings for the quarter ended Sep 30, 2026, 2 funds we track made a large change in BRVE: 2 opened a position or grew one by half or more, and none cut one by half or more.
- Fmr LLC added 7,585,769 shares.
- BlackRock, Inc. added 1,007,129 shares.
Get BRVE alerts
Set a BRVE price alert, or get one when a fund, insider or politician you follow trades.